30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Mark Corrigan

Track

Insider profile

Currently holds positions in Colucid Pharmaceuticals Inc, WAVE Life Sciences Ltd and Nabriva Therapeutics PLC

Performance

Overall performance
3.3
Performance over holding periods
3.3
30 days 90 days 120 days
Average return 16% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
1 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director Colucid Pharmaceuticals Inc Oct. 27, 2015 -
Independent Director WAVE Life Sciences Ltd Sept. 4, 2019 -
Independent Member of the Supervisory Board Nabriva Therapeutics PLC Aug. 1, 2016 -
Executive Chairman of the Board Novelion Therapeutics Inc July 3, 2018 - Sept. 24, 2019
Director Novelion Therapeutics Inc March 30, 2017 - July 3, 2018
Chairman of the Board EPIRUS Biopharmaceuticals Inc July 15, 2014 - July 25, 2016
Independent Director Cubist Pharmaceuticals LLC June 30, 2008 - Jan. 21, 2015
President, Chief Executive Officer, Director EPIRUS Biopharmaceuticals Inc Jan. 5, 2010 - July 15, 2014
Mark Corrigan's trades of WAVE Life Sciences Ltd's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-10 2025-12-08
PlS Planned sale
4,872 -7.7%
71.89
US$1,398,632 		4,872 -7.7% 71.89 US$1,398,632
2025-12-10 2025-12-08
PlS Planned sale
7,884 -28.3%
424.17
US$932,127 		7,884 -28.3% 424.17 US$932,127
2025-12-08 2025-12-08
PrS Proposed sale
61,741
81.21
US$4,415,509 		61,741 81.21 US$4,415,509
2022-08-04 2022-08-02
S Sale
10,297 -58.8%
0.19
US$1,956 		10,297 -58.8% 0.19 US$1,956
2004-05-12 2004-05-11
S Sale
15,000 -100.0%
46.59
US$698,850 		15,000 -100.0% 46.59 US$698,850
2004-05-12 2004-05-11
S Sale
5,000 -25.0%
46.54
US$232,700 		5,000 -25.0% 46.54 US$232,700
2004-05-12 2004-05-11
S Sale
5,000 -20.0%
46.11
US$230,550 		5,000 -20.0% 46.11 US$230,550
2004-05-12 2004-05-11
S Sale
5,000 -16.7%
46.25
US$231,250 		5,000 -16.7% 46.25 US$231,250
2004-05-12 2004-05-11
S Sale
5,000 -14.3%
46.05
US$230,250 		5,000 -14.3% 46.05 US$230,250
2004-05-12 2004-05-11
S Sale
5,000 -12.5%
46.11
US$230,550 		5,000 -12.5% 46.11 US$230,550
2004-05-12 2004-05-11
S Sale
5,000 -11.1%
45.95
US$229,750 		5,000 -11.1% 45.95 US$229,750
2004-05-12 2004-05-11
S Sale
15,000 -25.0%
46.15
US$692,250 		15,000 -25.0% 46.15 US$692,250
2004-05-12 2004-05-11
S Sale
10,000 -14.3%
46.05
US$460,500 		10,000 -14.3% 46.05 US$460,500
2004-05-12 2004-05-11
S Sale
5,000 -6.7%
46.13
US$230,650 		5,000 -6.7% 46.13 US$230,650
2004-05-12 2004-05-11
S Sale
10,000 -11.8%
46.01
US$460,100 		10,000 -11.8% 46.01 US$460,100
2004-05-12 2004-05-11
S Sale
10,000 -10.5%
46.10
US$461,000 		10,000 -10.5% 46.10 US$461,000